Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer
This Special Issue in Cancers is focused on cell therapy, bispecific antibodies, and other immunotherapies against cancer. It includes reports on cell therapies such as CAR-NK cell therapies, and bispecific antibodies against multiple myeloma and B cell lymphoma. Immunotherapies against solid tumors...
Saved in:
Other Authors: | |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_128869 | ||
005 | 20231130 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20231130s2023 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-9567-2 | ||
020 | |a 9783036595665 | ||
020 | |a 9783036595672 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-9567-2 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
072 | 7 | |a MJCL |2 bicssc | |
100 | 1 | |a Golubovskaya, Vita |4 edt | |
700 | 1 | |a Golubovskaya, Vita |4 oth | |
245 | 1 | 0 | |a Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
300 | |a 1 electronic resource (194 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a This Special Issue in Cancers is focused on cell therapy, bispecific antibodies, and other immunotherapies against cancer. It includes reports on cell therapies such as CAR-NK cell therapies, and bispecific antibodies against multiple myeloma and B cell lymphoma. Immunotherapies against solid tumors include TGF-beta-PDL-1 fusion protein and EpCAM-CD3 bispecific antibody generated with mRNA-lipid nanoparticles (LNP) against colorectal tumors. The clinical studies ongoing with bi- and tri-specific T cell engager antibodies against solid tumors and advantages versus cell therapies are discussed. This Special Issue highlights novel approaches to cell therapies, bispecific antibodies, vaccines, and immunotherapies that will be interesting for cancer cell researchers, biologists, and oncologists. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
650 | 7 | |a Oncology |2 bicssc | |
653 | |a cell therapy | ||
653 | |a bispecific antibody | ||
653 | |a chimeric antigen receptor | ||
653 | |a cancer | ||
653 | |a immunotherapy | ||
653 | |a vaccine | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/8339 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/128869 |7 0 |z DOAB: description of the publication |